Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma.

Dong X, Zhang R, He J, Lai L, Alolga RN, Shen S, Zhu Y, You D, Lin L, Chen C, Zhao Y, Duan W, Su L, Shafer A, Salama M, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC.

Aging (Albany NY). 2019 Aug 21;11(16):6312-6335. doi: 10.18632/aging.102189. Epub 2019 Aug 21.

2.

SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis.

Zhang R, Lai L, Dong X, He J, You D, Chen C, Lin L, Zhu Y, Huang H, Shen S, Wei L, Chen X, Guo Y, Liu L, Su L, Shafer A, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC.

Mol Oncol. 2019 May;13(5):1235-1248. doi: 10.1002/1878-0261.12482. Epub 2019 Apr 17.

3.

EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma.

Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T.

PLoS One. 2019 Jan 31;14(1):e0204186. doi: 10.1371/journal.pone.0204186. eCollection 2019.

4.

EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.

Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, Guo Y, Su L, Shafer A, Moran S, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC.

Epigenetics. 2019 Feb;14(2):118-129. doi: 10.1080/15592294.2019.1573066. Epub 2019 Jan 31.

PMID:
30665327
5.

DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients.

Guo Y, Zhang R, Shen S, Wei Y, Salama SM, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Su L, Zhu Z, Staaf J, Helland Å, Esteller M, Christiani DC.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1527-1535. doi: 10.1158/1055-9965.EPI-18-0454. Epub 2018 Sep 5.

PMID:
30185536
6.

A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer.

Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC.

Mol Oncol. 2018 Jun;12(6):913-924. doi: 10.1002/1878-0261.12204. Epub 2018 May 4.

7.

Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.

Wei Y, Liang J, Zhang R, Guo Y, Shen S, Su L, Lin X, Moran S, Helland Å, Bjaanæs MM, Karlsson A, Planck M, Esteller M, Fleischer T, Staaf J, Zhao Y, Chen F, Christiani DC.

Clin Epigenetics. 2018 Apr 2;10:41. doi: 10.1186/s13148-018-0474-3. eCollection 2018.

8.

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes.

Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å.

BMC Cancer. 2016 Feb 8;16:71. doi: 10.1186/s12885-016-2104-9.

9.

Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.

Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å.

Mol Oncol. 2016 Feb;10(2):330-43. doi: 10.1016/j.molonc.2015.10.021. Epub 2015 Nov 6.

10.

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas.

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A.

Int J Cancer. 2014 Oct 15;135(8):1812-21. doi: 10.1002/ijc.28828. Epub 2014 Mar 14.

Supplemental Content

Loading ...
Support Center